CG Oncology (NASDAQ:CGON) Director Brian Guan-Chyun Liu Acquires 371,085 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Brian Guan-Chyun Liu acquired 371,085 shares of CG Oncology stock in a transaction on Thursday, June 25th. The stock was purchased at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the purchase, the director owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. The trade was a 24.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

CG Oncology Price Performance

Shares of CGON opened at $73.73 on Tuesday. The stock has a market capitalization of $6.50 billion, a price-to-earnings ratio of -31.64 and a beta of 0.31. CG Oncology, Inc. has a 1 year low of $23.65 and a 1 year high of $75.50. The business’s 50 day simple moving average is $64.55 and its 200-day simple moving average is $58.34.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. On average, sell-side analysts expect that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Institutional Trading of CG Oncology

A number of institutional investors have recently bought and sold shares of the stock. Whittier Trust Co. of Nevada Inc. bought a new position in CG Oncology during the fourth quarter valued at $27,000. NFSG Corp purchased a new stake in shares of CG Oncology in the first quarter valued at $34,000. Comerica Bank lifted its holdings in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares during the last quarter. Fifth Third Bancorp bought a new stake in shares of CG Oncology in the 1st quarter worth about $74,000. Finally, KBC Group NV purchased a new position in shares of CG Oncology during the 1st quarter worth about $78,000. 26.56% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CGON has been the subject of a number of recent research reports. Truist Financial reissued a “buy” rating and issued a $82.00 price objective (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Wolfe Research began coverage on shares of CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a report on Monday, April 20th. Royal Bank Of Canada lifted their price target on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Finally, JPMorgan Chase & Co. boosted their price objective on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $81.73.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.